Johnson & Johnson (JNJ) – Analysts’ Weekly Ratings Changes

Johnson & Johnson (NYSE: JNJ) has recently received a number of price target changes and ratings updates:

• 12/18/2025 – Johnson & Johnson had its price target raised by analysts at The Goldman Sachs Group, Inc. from $213.00 to $240.00. They now have a “buy” rating on the stock.
• 12/17/2025 – Johnson & Johnson was given a new $240.00 price target on by analysts at Royal Bank Of Canada.
• 12/15/2025 – Johnson & Johnson had its price target raised by analysts at Bank of America Corporation from $204.00 to $220.00. They now have a “neutral” rating on the stock.
• 12/12/2025 – Johnson & Johnson had its price target raised by analysts at Morgan Stanley from $190.00 to $197.00. They now have an “equal weight” rating on the stock.
• 12/12/2025 – Johnson & Johnson had its price target raised by analysts at Wells Fargo & Company from $212.00 to $230.00. They now have an “overweight” rating on the stock.
• 12/11/2025 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at BMO Capital Markets.
• 12/11/2025 – Johnson & Johnson had its price target raised by analysts at Royal Bank Of Canada from $209.00 to $230.00. They now have an “outperform” rating on the stock.
• 12/11/2025 – Johnson & Johnson had its price target raised by analysts at Citigroup Inc. from $215.00 to $232.00. They now have a “buy” rating on the stock.
• 12/10/2025 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at HSBC Holdings plc. They now have a $240.00 price target on the stock.
• 12/5/2025 – Johnson & Johnson had its price target raised by analysts at Guggenheim from $206.00 to $227.00. They now have a “buy” rating on the stock.
• 12/2/2025 – Johnson & Johnson had its price target raised by analysts at Barclays PLC from $176.00 to $197.00. They now have an “equal weight” rating on the stock.
• 11/13/2025 – Johnson & Johnson is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $230.00 price target on the stock.
• 11/12/2025 – Johnson & Johnson was upgraded by analysts at Scotiabank to a “strong-buy” rating.
• 10/31/2025 – Johnson & Johnson had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.